Yvonne Summers

12.2k total citations
65 papers, 1.2k citations indexed

About

Yvonne Summers is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Molecular Biology. According to data from OpenAlex, Yvonne Summers has authored 65 papers receiving a total of 1.2k indexed citations (citations by other indexed papers that have themselves been cited), including 46 papers in Oncology, 45 papers in Pulmonary and Respiratory Medicine and 12 papers in Molecular Biology. Recurrent topics in Yvonne Summers's work include Lung Cancer Treatments and Mutations (37 papers), Lung Cancer Research Studies (20 papers) and Cancer Immunotherapy and Biomarkers (14 papers). Yvonne Summers is often cited by papers focused on Lung Cancer Treatments and Mutations (37 papers), Lung Cancer Research Studies (20 papers) and Cancer Immunotherapy and Biomarkers (14 papers). Yvonne Summers collaborates with scholars based in United Kingdom, United States and Germany. Yvonne Summers's co-authors include Rohit Lal, Mayukh Das, Carla Visseren‐Grul, Daniel C. Christoph, Fiona Maxwell, J. Cadranel, T. Benepal, D. Ferry, Judith Carser and Mark R. Middleton and has published in prestigious journals such as Journal of Clinical Oncology, Cancer and Cancer Research.

In The Last Decade

Yvonne Summers

60 papers receiving 1.2k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Yvonne Summers United Kingdom	18	628	435	395	166	113	65	1.2k
Sander Bins Netherlands	17	688 1.1×	324 0.7×	376 1.0×	117 0.7×	113 1.0×	59	1.2k
Alberto D’Angelo United Kingdom	18	449 0.7×	382 0.9×	348 0.9×	188 1.1×	66 0.6×	59	1000
Paolo Bironzo Italy	18	505 0.8×	637 1.5×	334 0.8×	191 1.2×	74 0.7×	100	1.2k
Della Makower United States	17	680 1.1×	254 0.6×	441 1.1×	290 1.7×	50 0.4×	55	1.2k
Sojiro Kusumoto Japan	19	522 0.8×	485 1.1×	349 0.9×	117 0.7×	79 0.7×	49	1.0k
Yüksel Küçükzeybek Türkiye	20	728 1.2×	298 0.7×	215 0.5×	225 1.4×	116 1.0×	102	1.2k
Polly Niravath United States	14	456 0.7×	209 0.5×	195 0.5×	227 1.4×	71 0.6×	53	970
Carmela Romano Italy	20	449 0.7×	307 0.7×	231 0.6×	116 0.7×	98 0.9×	76	1.5k
Muhammad Salim United States	15	698 1.1×	250 0.6×	260 0.7×	166 1.0×	124 1.1×	42	1.1k
Stephen M. Schleicher United States	19	373 0.6×	230 0.5×	609 1.5×	171 1.0×	117 1.0×	62	1.3k

Countries citing papers authored by Yvonne Summers

Since Specialization

Citations

This map shows the geographic impact of Yvonne Summers's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Yvonne Summers with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Yvonne Summers more than expected).

Fields of papers citing papers by Yvonne Summers

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Yvonne Summers. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Yvonne Summers. The network helps show where Yvonne Summers may publish in the future.

Co-authorship network of co-authors of Yvonne Summers

This figure shows the co-authorship network connecting the top 25 collaborators of Yvonne Summers. A scholar is included among the top collaborators of Yvonne Summers based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Yvonne Summers. Yvonne Summers is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Carter, Mathew, Raffaele Califano, Yvonne Summers, et al.. (2025). First-line osimertinib compared to earlier generation TKIs in advanced EGFR-mutant NSCLC: A real-world survival analysis. Lung Cancer. 200. 108084–108084. 2 indexed citations

Longo, Vito, Domenico Galetta, Sara Pilotto, et al.. (2025). Correlation between irAEs and survival outcomes in patients with ES-SCLC treated with first-line chemoimmunotherapy. European Journal of Cancer. 221. 115435–115435. 2 indexed citations

Savage, Joshua, Yvonne Summers, Alastair Greystoke, et al.. (2023). Abstract A115: mTOR targeting in STK11 deficient Non-Small Cell Lung Cancer (NSCLC): final results, pre-clinical rationale and biomarker analysis of a phase II trial of the mTORC1/2 inhibitor vistusertib in STK11 deficient lung adenocarcinoma (NLMT B2). Molecular Cancer Therapeutics. 22(12_Supplement). A115–A115.

Pearce, Mark S., Fábio Gomes, Colin R. Lindsay, et al.. (2023). 82P The role of circadian rhythms in NSCLC immunotherapy efficacy: A focus on first dose timing. Immuno-Oncology Technology. 20. 100554–100554. 1 indexed citations

Hodgson, Clare, Mathew Carter, Colin R. Lindsay, et al.. (2022). Real-World Data on Pembrolizumab for Pretreated Non-Small-Cell Lung Cancer: Clinical Outcome and Relevance of the Lung Immune Prognostic Index. Targeted Oncology. 17(4). 453–465. 7 indexed citations

Shim, Byoung Yong, Javier de Castro, Manuel Cobo, et al.. (2020). 1269P EMPOWER-lung 4: Phase II, randomized, open-label high dose or standard dose cemiplimab alone/plus ipilimumab in the second-line treatment of advanced non-small cell lung cancer (NSCLC). Annals of Oncology. 31. S820–S820. 7 indexed citations

Middleton, Gary, Kristian Brock, Joshua Savage, et al.. (2020). Pembrolizumab in patients with non-small-cell lung cancer of performance status 2 (PePS2): a single arm, phase 2 trial. The Lancet Respiratory Medicine. 8(9). 895–904. 113 indexed citations

Middleton, Gary, Sanjay Popat, Yvonne Summers, et al.. (2019). PL02.09 National Lung Matrix Trial (NLMT): First Results from an Umbrella Phase II Trial in Advanced Non-Small Cell Lung Cancer (NSCLC). Journal of Thoracic Oncology. 14(10). S7–S7. 1 indexed citations

Mueller, Julia, Alan Davies, Caroline Jay, et al.. (2018). Developing and testing a web‐based intervention to encourage early help‐seeking in people with symptoms associated with lung cancer. British Journal of Health Psychology. 24(1). 31–65. 7 indexed citations

10.

Charalambous, Andreas, Alex Molassiotis, Yvonne Summers, Z. Stamataki, & Paul Taylor. (2017). NU05.01 Use of Inspiratory Muscle Training in Managing Dyspnoea in Lung Cancer Patients. Journal of Thoracic Oncology. 12(1). S206–S208. 5 indexed citations

11.

Cree, Ian A., Richard Booton, Paul Cane, et al.. (2016). PD‐L1 testing for lung cancer in the UK: recognizing the challenges for implementation. Histopathology. 69(2). 177–186. 65 indexed citations

12.

Summers, Yvonne, J. Cadranel, T. Benepal, et al.. (2016). Cisplatin in the modern era: The backbone of first-line chemotherapy for non-small cell lung cancer. Cancer Treatment Reviews. 44. 42–50. 311 indexed citations

13.

Dean, Emma, Nicola Steele, Hendrik‐Tobias Arkenau, et al.. (2016). SELECT-3: A phase I study of selumetinib in combination with platinum doublet chemotherapy for advanced NSCLC in the first-line setting. Annals of Oncology. 27. vi439–vi439. 2 indexed citations

14.

Heigener, David F., Maya Gottfried, Jaafar Bennouna, et al.. (2016). Efficacy and safety of nintedanib (NIN)/docetaxel (DOC) in patients with lung adenocarcinoma: Further analyses from the LUME-Lung 1 study. Annals of Oncology. 27. vi442–vi442. 2 indexed citations

15.

Howell, M., et al.. (2015). Outcomes of Octogenarian (≥80 YO) Patients with Advanced Non-Small Cell Lung Cancer (NSCLC): a Single Institution Experience from the Christie Hospital. Annals of Oncology. 26. i29–i29. 1 indexed citations

16.

Evison, Matthew, Philip Crosbie, Raffaele Califano, et al.. (2015). Can EBUS-TBNA Provide an Accurate Diagnosis in Patients Found to Have Enlarged or FDG-avid Lymph Nodes During Surveillance of Previously Treated Lung Cancer?. Journal of Bronchology & Interventional Pulmonology. 22(2). 114–120. 5 indexed citations

17.

Natale, Ronald B., Fiona Blackhall, Dariusz M. Kowalski, et al.. (2014). Evaluation of Antitumor Activity Using Change in Tumor Size of the Survivin Antisense Oligonucleotide LY2181308 in Combination with Docetaxel for Second-Line Treatment of Patients with Non–Small-Cell Lung Cancer: A Randomized Open-Label Phase II Study. Journal of Thoracic Oncology. 9(11). 1704–1708. 30 indexed citations

18.

Carser, Judith & Yvonne Summers. (2006). Trichomegaly of the Eyelashes After Treatment with Erlotinib in Non-small Cell Lung Cancer. Journal of Thoracic Oncology. 1(9). 1040–1041. 20 indexed citations

19.

Summers, Yvonne, et al.. (2002). Effect of temozolomide on central nervous system relapse in patients with advanced melanoma. Melanoma Research. 12(2). 175–178. 87 indexed citations

20.

White, Shane, Paul Lorigan, Mark R. Middleton, et al.. (2001). Randomized phase II study of cyclophosphamide, doxorubicin, and vincristine compared with single-agent carboplatin in patients with poor prognosis small cell lung carcinoma. Cancer. 92(3). 601–608. 37 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact